Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. (Nasdaq: DXCM), today announced that the Tandem Mobi insulin pump with Control-IQ technology is now fully compatible with both the Dexcom G7 ...

Tandem Diabetes’ t:slim X2 Insulin Pump has received FDA approval for use alongside Dexcom’s G5 Mobile continuous glucose monitoring (CGM) technology. The approval is part of a rapid evolution ...

In May 2024, the Tandem Mobi insulin pump with Control-IQ technology completed integration with both Dexcom G7 and Dexcom G6 CGM Systems. With this, Tandem Diabetes became the only company that ...

slim X2 pump, completed its integration with both the Dexcom G7 and Dexcom G6 CGM systems. With this, Tandem Diabetes became ...

Abbott began partnering with insulin pump manufacturers nearly five ... devices made by both Abbott and Dexcom — which is something that Tandem has done as well. “This type of collaboration ...

DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

Today, Benzinga 's options scanner spotted 8 uncommon options trades for DexCom. This isn't normal. The overall sentiment of ...

and Dexcom, Inc. (Nasdaq: DXCM), today announced that the Tandem Mobi insulin pump with Control-IQ technology is now fully compatible with both the Dexcom G7 and Dexcom G6 Continuous Glucose ...

New over-the-counter sensors, an Abbott-Medtronic partnership and Roche’s first CGM are among diabetes technology’s top stories so far in 2024. Check out MedTech Dive’s roundup of the latest news.